Exosome Diagnostics and Therapeutics Market
Number of pages: 100 | Report Format: PDF | Published date: February 02, 2023
Historical Years – 2020 | Base Year – 2021 | Forecasted Years – 2022-2030
|
Report Attribute |
Details |
|
Market Size Value in 2021 |
US$ 98 million |
|
Revenue Forecast in 2030 |
US$ 1560 million |
|
CAGR |
36% |
|
Base Year for Estimation |
2021 |
|
Forecast Period |
2022-2030 |
|
Historical Year |
2020 |
|
Segments Covered |
Product Type, Application, End User, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, and the Rest of the World (RoW) |
According to the deep-dive market assessment study by Growth Plus Reports, the global exosome diagnostics and therapeutics market was valued at US$ 98 million in 2021 and is expected to register a revenue CAGR of 36% to reach US$ 1560 million by 2030.
Exosome Diagnostics And Therapeutics Market Fundamentals
Exosomes are extracellular vesicles produced by cells, which contain metabolites, proteins, lipids, and nucleic acids. They influence different facets of cell biology and act as intermediaries of close and far intercellular communication in health and illness. Applications of exosomes are linked to immunological responses, viral pathogenicity, pregnancy, cardiovascular illnesses, diseases of the central nervous system, and cancer development. Exosomes effectively transfer biomolecules, such as proteins, metabolites, and nucleic acids, into target cells to change their biological response. Exosomes are made to carry a range of therapeutic payloads, such as short-interfering RNAs (RNAs), immunological modulators, antisense oligonucleotides, chemotherapeutic medicines, and immunological agents. Exosome vesicle-based liquid biopsy may be used to diagnose individuals with cancer and other disorders, and to predict their prognosis modulators that may target their distribution to a specific area.
Exosomes act as intercellular messengers, have distinctive payloads, are highly prevalent in almost all biofluids, and have high biological stability. Therefore, it was only natural to investigate their potential as biomarkers in liquid biopsy. Exosomes’ involvement in specific diseases, such as chronic obstructive pulmonary disease, lends more evidence to their usefulness as biomarkers. Exosomes also have diagnostic value outside of the cancer field; these include pain, autoimmune diseases, and hypertensive disorders of pregnancy.
Exosomes are increasingly being recognized as potential therapies due to their capacity to incite strong cellular responses both in vitro and in vivo. Exosomes, made up of cellular membranes with several sticky proteins on their surface, are known to be particularly adept at facilitating cell-cell contact and offer a unique method for delivering diverse therapeutic drugs to target cells. Exosomes are being increasingly recognized as novel modulators for various therapeutic uses, including immunization, biological targeting agents, and drug delivery systems. Therapeutic exosome systems can be broadly segmented into two categories: artificial exosomes and naive exosomes: Therapeutic exosomes, called naive exosomes, come from non-engineered cells that produce them. Artificial exosomes are therapeutic, either generated in vitro after isolation or derived from altered-producing cells.
[6363463]
Exosome Diagnostics And Therapeutics Market Dynamics
The rise in the prevalence of chronic diseases, infectious diseases, autoimmune diseases, and cancer, as well as the increase in demand for molecular diagnosis, are the main factors driving the exosome diagnostic and therapeutic market revenue growth. Additionally, continuous advancements in drug development and discovery in exosome technologies provide important insights into biological heterogeneity and function and improve the capacity to harness the therapeutic and diagnostic potential for infectious disease and cancer. Therefore, the development of the exosome diagnostic and therapeutic markets is fueled by technological advancements in the healthcare industry. Exosome technologies are used as diagnostic and therapeutic tools in the treatment of various diseases, such as neurodegeneration, cardiovascular dysfunction, and cancer. This has led to an increase in the demand for drug therapies and a surge in R&D activities in the pharmaceutical and biopharmaceutical fields. Exosomes may one day be used to diagnose cancer, and the advancement of translational precision medicine is likely to boost their usage in diagnostic and therapeutic procedures, spurring the development of the exosome diagnostic and therapeutic market.
Regulations associated with exosome product approvals and commercialization are stringent, which may impede the industry's expansion during the forecast period. In addition, the increase over the research period can be hampered by technological issues related to using exosomes in various applications. The lack of effective transfection techniques and the requirement for method tuning are two main obstacles. These difficulties are projected to hamper market expansion.
Exosome Diagnostics and Therapeutics Market Ecosystem
The global exosome diagnostics and therapeutics market has been analyzed from four perspectives: product type, application, end user, and region.
Exosome Diagnostics and Therapeutics Market by Product Type
[3563622]
Based on the product type, the global exosome diagnostics and therapeutics market has been segmented into kits & reagents, instruments, and services & software.
The kits & reagents segment accounts for the biggest revenue share of the global exosome diagnostics and therapeutics market. Extracellular vesicle isolation can be a laborious, challenging, and non-specific technique. As a result, leading companies are releasing cutting-edge kits and reagents to expand the uses of exosomes, driving the segment’s expansion.
Exosome Diagnostics and Therapeutics Market by Application
Based on the application, the global exosome diagnostics and therapeutics market has been segmented into cancer, cardiovascular diseases, infectious diseases, and others.
Due to the wide range of uses for exosomes in cancer diagnosis, prognosis, and therapy, the cancer application sector leads the global exosome diagnostics and therapeutics market. Nano-sized membrane vesicles called cancer-related exosomes significantly impact the tumor microenvironment. New research suggests that exosomes can carry specific payloads, including proteins and nucleic acids, indicative of the state of tumors. Exosomes are, therefore, utilized as prognostic and diagnostic indicators for various malignancies.
Exosome Diagnostics and Therapeutics Market by End User
Based on the end user, the global exosome diagnostics and therapeutics market has been segmented into pharmaceutical & biotechnology companies, hospitals & diagnostic centers, and cancer institutes.
During the forecast period, the hospitals sector is anticipated to register revenue growth at a higher CAGR during the forecast period. High-end technical goods and the wide availability of instruments and reagents are predicted to fuel segment expansion. In addition, increased cancer rates, the need for immunizations, and highly qualified medical experts in hospitals help hospitals to gain a dominant market revenue share. Favorable reimbursement schemes are further increasing the need for hospitals for hospital procedures and upgrades to healthcare facilities.
Exosome diagnostics and therapeutics market by Region
Based on the region, the global exosome diagnostics and therapeutics market has been segmented into North America, Europe, Asia Pacific, and the Rest of the World.
With a large revenue share, the U.S. dominates the North America market, and it is anticipated to continue to develop rapidly during the period. Germany showed Y-O-Y growth in the Western European exosome diagnostic and therapeutic market in 2021. By the end of 2030, it is anticipated to possess a larger market revenue share. The growth is linked to Germany’s growing focus on exosome applications for accessing stem cells’ therapeutic effects in research operations. The increased cancer incidence in Germany and the need for sophisticated diagnostic tests are the main drivers of this revenue growth.
The market in China controlled most of the revenue share of the Asia Pacific market in 2021, and it is expected to develop at a profitable pace during the forecast period. The rise in clinically investigated and observed exosome applications is attributed to China’s expanding exosome diagnostic and therapeutic business.
Exosome Diagnostics And Therapeutics Market Competitive Landscape
The prominent players operating in the global exosome diagnostics and therapeutics market are:
Exosome Diagnostics And Therapeutics Market Strategic Developments
The global exosome diagnostics and therapeutics market is expected to register a revenue CAGR of 36% during the forecast period from 2022 to 2030.
Codiak Biosciences, Danaher Corp., Fujifilm Holdings Corp., Lonza Group AG, and Miltenyi Biotec are among the key players in the global exosome diagnostics and therapeutics market.
The kits and reagents segment dominates the global exosome diagnostics and therapeutics market.
Asia Pacific is expected to register the highest revenue growth in the exosome diagnostics and therapeutics market during the forecast period.
The global exosome diagnostics and therapeutics market was valued at US$ 98 million in 2021.
*Insights on financial performance are subject to the availability of information in the public domain